Longitudinal modeling of neurodegenerative diseases rem- ains a major challenge due to the complexity of the underlying processes and the strong heterogeneity of individual trajectories. Neuroimaging provides a unique opportunity to characterize disease-related alterations long before clinical onset, enabling earlier intervention. In this work, we employ a Variational Autoencoder (VAE) to compress high-dimensional neuroimaging scans into a low-dimensional latent representation ( \(z_0\) ) that captures dementia-related patterns. We then model the temporal evolution of this neuroimaging biomarker using a Bayesian longitudinal framework that incorporates genetic information as covariates. This approach allows us to study population-level disease trajectories while explicitly accounting for genetic risk factors. Our results show that the proposed neuroimaging biomarker \(z_0\) and the Bayesian longitudinal model successfully stratifies subjects into genotype-dependent risk subgroups, revealing distinct baseline profiles and progression patterns consistent with known genetic effects.

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Longitudinal Modeling of Alzheimer’s Disease Progression Using a Bayesian Latent Framework with APOE-Dependent Genetic Effects

  • C. Vázquez-García,
  • F. J. Martínez Murcia,
  • F. Segovia,
  • A. Forte,
  • J. Ramírez,
  • I. Illán,
  • A. Hernández-Segura,
  • C. Jiménez-Mesa,
  • J. M. Górriz

摘要

Longitudinal modeling of neurodegenerative diseases rem- ains a major challenge due to the complexity of the underlying processes and the strong heterogeneity of individual trajectories. Neuroimaging provides a unique opportunity to characterize disease-related alterations long before clinical onset, enabling earlier intervention. In this work, we employ a Variational Autoencoder (VAE) to compress high-dimensional neuroimaging scans into a low-dimensional latent representation ( \(z_0\) ) that captures dementia-related patterns. We then model the temporal evolution of this neuroimaging biomarker using a Bayesian longitudinal framework that incorporates genetic information as covariates. This approach allows us to study population-level disease trajectories while explicitly accounting for genetic risk factors. Our results show that the proposed neuroimaging biomarker \(z_0\) and the Bayesian longitudinal model successfully stratifies subjects into genotype-dependent risk subgroups, revealing distinct baseline profiles and progression patterns consistent with known genetic effects.